Lipoprotein changes and increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia.
Modifications in plasma low and high density lipoprotein (LDL and HDL) subfraction distribution, as well as the regulation of cellular LDL metabolism by hypertriglyceridemic LDL were tested before and after treatment with acipimox, a nicotinic acid derivative, in 11 type IV hyperlipidemic patients. Large, less dense LDL particles were found in plasma after acipimox treatment, reflecting compositional changes, characterized by a 25.4% increase in cholesteryl ester content and by a 46.2% reduction of triglycerides in LDL. HDL subfractions were only slightly modified, with an increase of dense, cholesteryl ester-enriched and triglyceride poor HDL3 particles. The LDL (B,E) receptor activity in humans skin fibroblasts of LDL isolated before and after treatment was also evaluated. Hypertriglyceridemic LDL proved rather inefficient in regulating receptor activity with a close to 30% reduction vs. normal LDL in the capacity to inhibit receptor-mediated uptake and degradation of 125I-LDL. Such abnormality was fully corrected after acipimox. The reported findings indicate that acipimox treatment in type IV patients, in spite of a relatively modest plasma triglyceride reduction, can markedly modify LDL distribution and composition, normalizing the defective interaction of hypertriglyceridemic LDL with the LDL (B,E) receptor.
Franceschini
G
G
Center E. Grossi Paoletti, Institute of Pharmacological Sciences, University of Milan, Italy.
Bernini
F
F
Michelagnoli
S
S
Bellosta
S
S
Vaccarino
V
V
Fumagalli
R
R
Sirtori
C R
CR
D006801:Humans; D015228:Hypertriglyceridemia / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000378:metabolism; D008297:Male; D011719:Pyrazines / Q000627:therapeutic use*; D011973:Receptors, LDL / Q000187:drug effects* / Q000378:metabolism
D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D011719:Pyrazines; D011973:Receptors, LDL; C027696:acipimox